Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hydrocodone Gets Advisory Committee Review, Offering Congress A Scheduling Out

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA announces the October meeting unusually early following legislative efforts to further restrict access to the opioid pain reliever due to abuse worries.

You may also be interested in...



Hydrocodone Reclassification Could Benefit Long-Acting Opioids

FDA’s recommendation that combination hydrocodone products be moved to the more restrictive Schedule II will increase the regulatory burdens for physicians and pharmacies while making the already restricted extended-release oxycodone products relatively more appealing.

Hydrocodone Combination Up-scheduling Marches Forward Despite FDA Ambivalence

FDA’s Drug Safety and Risk Management Advisory Committee votes 19-10 to move the opioid drugs to the more restrictive Schedule II because their abuse potential is similar to other drugs already that already have the controlled substances designation.

PDUFA Final Legislation: House Pays For Senate’s GAIN

Resolution of issues in conference committee largely favors the brand industry, and swift passage will allow the legislation to avoid becoming a political football after the Supreme Court’s ruling on health care reform.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074251

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel